IL6 and congenital rubella syndrome: IL-6, in particular, has been highly implicated in CRS and COVID-19 severity, and inhibition of IL-6/IL-6R activity may lead to improved patient outcome, increasing its desirability as a target (Figure 1) (Scheller et al., 2014; Tanaka et al., 2016; Zhang C. et al., 2020).